Abstract

Abstract Early diagnosis of cancer has become one of the effective ways to prevent and treat cancer. At present, magnetic resonance imaging (MRI) diagnosis based on nanosized iron oxide with no toxicity and excellent biocompatibility has attracted much attention. But the poor stability of magnetic fluid (MF) is becoming more and more prominent. In view of the poor stability of MF, the dodecanethiol-poly(methacrylic acid) (DDT-PMAA) as an outer shell was prepared for the MFs (Fe3O4@DDT-PMAA MF) to improve the stability. We also compared the amount of reactants, the ratio of reactants, and the reaction temperature, and finally screened out the best reaction conditions, so as to get more stable products. The stability of the system was studied by visual observation, stability index (I), and magnetic weight change. The results demonstrated that Fe3O4@DDT-PMAA can be stable for more than 60 days. The T 1 mapping image showed that the longitudinal relaxivity (r 1) value was 6.9 mM−1 s−1 (1.5 T, room temperature), which was higher than the commercial contrast agent SHU-555 (r 1 = 2.9 mM−1 s−1), but the transverse relaxivity (r 2) value accounted for 64.48% of the commercial contrast agent Feridex (r 2 = 67.8 mM−1 s−1, 1.5 T, room temperature) because the outermost layer was encapsulated by a polymer. In addition, the imaging effect was more vivid and there was almost no background interference of T 1- and T 2-weighted images in vivo, which indicated that the Fe3O4@DDT-PMAA MF exhibited excellent potential in MRI applications.

Highlights

  • At present, cancer is still one of the diseases that cannot be overcome completely

  • Polymer DDT-PMAA was synthesized by DDT and methacrylic acid (MAA) with different molar ratios (0.5, 1, and 2%)

  • The hydrodynamic diameter distributions of the NPs obtained by the laser particle size analyzer (DLS) show that the particle distribution of Fe3O4 magnetic fluid (MF) modified by polymer DDT-PMAA with three different ratios were different (Figure 1)

Read more

Summary

Introduction

Cancer is still one of the diseases that cannot be overcome completely. The early diagnosis of cancer is very important for its treatment[1]. Magnetic resonance imaging (MRI) is a very effective test method. Compared with CT and X-ray imaging, MRI has no radiation damage and has high soft tissue resolution, which can be applied to diagnose a variety of tumors [2]. Conventional MRI contrast agent such as gadolinium (Gd) reagent is expensive and owns certain nephrotoxicity, which fails to use as a diagnostic drug over a long time [3]. It is imperative to develop new contrast agents with good imaging effect and excellent biocompatibility, especially with long-term stability [4]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call